Dr. Elizabeth K. Lee discusses the RAINFOL-01 clinical trial evaluating treatment with Rina-S in advanced ovarian cancer.

The European Commission (EC) has granted marketing authorisation to AbbVie’s Elahere (mirvetuximab soravtansine) for the treatment of folate receptor-alpha (FRα) platinum-resistant ovarian ...

Elahere showed superior efficacy over chemotherapy in progression-free survival, objective response rate, and overall survival in the MIRASOL trial. The treatment reduced the risk of tumor progression ...

Elahere shows a 37% lower risk of tumor progression or death vs. chemotherapy, with a median PFS of 5.59 months vs. 3.98 months. Patients on Elahere have a median overall survival of 16.85 months ...

Discover AbbVie's strong performance, with immunology growth and undervaluation despite challenges. Click here to read an ...

Elahere (mirvetuximab soravtansine-gynx) is a brand-name injection that’s prescribed for certain types of cancer. Elahere has interactions with some other drugs. Examples include certain ...

ImmunoGen, Inc. has announced that its platinum-resistant ovarian cancer drug ELAHERE (mirvetuximab soravtansine-gynx) has been granted FDA accelerated approval. This first FDA antibody-drug ...

Elahere generated sales worth $331 million during the first nine months of 2024. The drug is also being studied for earlier lines of therapy in ovarian cancer. Potential label expansion of the ...

Mirvetuximab soravtansine-gynx shows superior progression-free and overall survival in FRα+, platinum-resistant ovarian cancer compared to chemotherapy. The treatment achieved a higher objective ...

Mirvetuximab soravtansine shows no significant HRQoL detriments despite TEOEs in FRα+ platinum-resistant ovarian cancer patients. The phase 3 MIRASOL trial confirms improved progression-free and ...

AbbVie’s Elahere (mirvetuximab soravtansine-gynx) has demonstrated consistent survival benefits in a subset of ovarian cancer patients, according to results from a confirmatory late-stage trial of the ...